Physician profile
Megan Johnson
NPI 1336288984
$2,376.49
in general payments reported to CMS, 2019-2025
27 companies · $995 in 2025
The $995 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.32 · 2020: $27.48 · 2021: $64.92 · 2022: $159 · 2023: $222 · 2024: $892 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.94 | 2022-2025 | |
| Daiichi Sankyo INC. | $459.87 | 2024-2025 | Injectafer |
| Boston Scientific Corporation | $183.16 | 2025 | Axios |
| Pfizer INC. | $166.44 | 2019-2025 | |
| Indivior INC. | $152.16 | 2024-2025 | Sublocade |
| Novo Nordisk INC | $132.61 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $112.82 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Alk-Abello, INC | $79.01 | 2024-2025 | Odactra, Grastek |
| Exact Sciences Corporation | $71.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $65.27 | 2025 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $59.84 | 2020-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.09 | 2021 | |
| Sanofi Pasteur INC. | $44.84 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.38 | 2023-2024 | Xifaxan |
| Dexcom, INC. | $30.33 | 2025 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $28.46 | 2024 | Rebyota |
| Gilead Sciences, INC. | $27.62 | 2025 | Yeztugo |
| Aimmune Therapeutics, INC. | $25.62 | 2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.52 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $22.81 | 2022 | |
| Qiagen, LLC | $21.41 | 2024 | |
| Janssen Biotech, INC. | $18.83 | 2023 | Tremfya |
| Glaxosmithkline, LLC. | $17.57 | 2024 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $17.46 | 2023 | Veozah |
| Kyowa Kirin, INC. | $16.26 | 2023 | Crysvita |
| Genentech USA, INC. | $14.97 | 2020 | |
| Almatica Pharma LLC | $14.30 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.